Please assess the completion status of the following clinical trial:

Trial Title: Sentinel™ Trial: A Prospective Study Evaluating the Performance and Clinical Benefit of Personalized ctDNA-based MRD Testing to Detect Recurrence and Monitor Treatment Response in Patients With Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Study participants must meet all the inclusion criteria below to enroll:~1. Male or female participants ≥ 18 years of age;~2. Confirmed diagnosis of a stage 1-3 solid tumor;~3. Curative surgery or definitive therapy (e.g., chemoradiation, stereotactic body radiation therapy \[SBRT\]) completed \<5 years ago without any current evidence of radiographical or biochemical recurrence, or planned within 28 days of consent;~4. Surplus formalin fixed paraffin embedded tumor specimen available;~5. Able to tolerate venipuncture for blood draws;~6. Primary diagnosis is not glioma or CNS disease;~7. Both the tumor tissue sample and blood sample pass the quantity and quality parameters to allow for a successful MRD test result.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).